Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study.
Pallawi TorkaOthman Salim AkhtarNishitha M ReddyBora E BaysalAngela KaderAdrienne GromanJenna NicholsCory MavisJoseph D TarioAnneMarie W BlockSheila N J SaitPaola GhioneSuchitra SundaramEugene R PrzespolewskiAlice MohrIan LundJessica KostrewaKenneth McWhiteJoseph DeMarcoMichael JohnsonAndrea DarrallRosh-Neke Thomas-TalleyPaul K WallaceVishala NeppalliAlan HutsonFrancisco J Hernandez-IlizaliturriPublished in: Cancer (2022)
The addition of ofatumumab to HyperCVAD/HD-MA led to high rates of MRD negativity by flow cytometry in patients with newly diagnosed MCL. Achieving a CR post-induction by both imaging and flow cytometry is associated with improved overall survival.